{"id":"NCT01128894","sponsor":"GlaxoSmithKline","briefTitle":"A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.","officialTitle":"A Randomized, Open-Label, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-05","primaryCompletion":"2011-09","completion":"2011-09","firstPosted":"2010-05-24","resultsPosted":"2014-05-20","lastUpdate":"2017-02-23"},"enrollment":841,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"BIOLOGICAL","name":"albiglutide","otherNames":[]},{"type":"DRUG","name":"liraglutide","otherNames":[]}],"arms":[{"label":"albiglutide","type":"EXPERIMENTAL"},{"label":"liraglutide","type":"ACTIVE_COMPARATOR"}],"summary":"This open-label study examines the efficacy and safety of albiglutide as compared with liraglutide in subjects with type 2 diabetes.","primaryOutcome":{"measure":"Mean Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 32","timeFrame":"Baseline and Week 32","effectByArm":[{"arm":"Albiglutide 50 mg","deltaMin":-0.78,"sd":0.047},{"arm":"Liraglutide 1.8 mg","deltaMin":-0.99,"sd":0.046}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0846"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":15},"locations":{"siteCount":173,"countries":["United States","Australia","Israel","Peru","Philippines","South Korea","Spain","United Kingdom"]},"refs":{"pmids":["24703047"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":404},"commonTop":["Nausea","Hypoglycaemia","Diarrhoea","Upper respiratory tract infection","Vomiting"]}}